A 20-year study of autoimmune polyendocrine syndrome type II and III in Taiwan
Authors' conclusion
This study provides the most comprehensive analysis of APS II and APS III in Asia. The percentage of patients with APS II was significantly lower than in the Western population. A second autoimmune endocrinopathy may develop several years after the first one. APCA examination is valuable when evaluating anemia in patients with APS.
Study context
- Population
- Patients aged ≥20 years diagnosed with autoimmune polyendocrine syndrome (APS) II or APS III in ten hospitals in Taiwan, 2001–202145 men · 142 women
- Participants
- 187 patients
- Exposure
- APS II vs APS III
- APS IIn = 7
- Outcome
- Distribution of APS type
Methodological detailsmulticentre (ten hospitals)
- Multicentre (ten hospitals)
Main finding
As reported in the abstract
APS II
3.7%
7
Patients
- Developed hyperthyroidism
- 55
- Developed hypothyroidism
- 44
Observational data: associations, not effects.
Further findings
Age at APS diagnosis by sex · younger age in men
P = 0.007
Thyroid dysfunction risk per year older at APS III diagnosis
- Increase in hyperthyroidism risk per year (P = 0.002)
- 3.6%
- Increase in hypothyroidism risk per year (P = 0.035)
- 3.7%
- Positive correlation between age at diagnosis and likelihood of thyroid dysfunction
Anti-parietal cell antibodies and anemia in APS III
- Positive anti-parietal cell antibodies (APCA) associated with higher risk of anemia (P < 0.001)
Original publication
A 20-year study of autoimmune polyendocrine syndrome type II and III in Taiwan. Eur Thyroid J. Published 23 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →